MedTech Dive September 24, 2024
The latest investment extends an earlier funding round, bringing the total raised to $82 million. Novo Holdings, the controlling shareholder of Novo Nordisk, joined returning investors.
Dive Brief:
- Route 92 Medical received a $50 million investment to support the global commercialization of its neurovascular intervention products, the company said Monday.
- The latest investment extends a November financing round, bringing the total raised to $82 million. Along with global commercialization, the additional funding will help support the company’s plans to pursue regulatory authorizations in new geographies.
- Route 92 sells devices for inserting microcatheters into neurovascular blood vessels and for the revascularization of patients with acute ischemic stroke. The company has received a series of 510(k) clearances for its devices.
Today's Sponsors
Today's Sponsor